Quick guide for acute angle-closure glaucoma

Diagnostic approach

  • Visual acuity testing
  • Visual field testing
  • Tonometry
  • Slit-lamp examination or direct fundoscopy (with undilated pupils)

Do not use mydriatic agents (e.g., atropine) during ophthalmologic examination in patients with acute angle-closure glaucoma.

Red flag features

  • Sudden onset
  • Painful red eye
  • Vision changes
  • Cloudy cornea
  • Mid-dilated, irregular, and/or unresponsive pupil
  • IOP > 21 mm Hg

Management checklist

  • Consult ophthalmology urgently.
  • Place the patient in a supine position.
  • Administer topical ophthalmic therapy (in succession, one minute apart):
    • Pilocarpine
    • Apraclonidine
    • Timolol (unless there are contraindications to beta-blockers)
  • Start systemic therapy: acetazolamide OR methazolamide .
  • Analgesics and/or antiemetics

If the IOP of the contralateral eye is elevated > 21 mm Hg, treat even if asymptomatic.

Summary

Glaucoma is a group of eye diseases associated with acute or chronic destruction of the optic nerve with or without concomitant increased intraocular pressure (IOP). In the US, glaucoma is the second leading cause of blindness in adults following age-related macular degeneration (AMD). The two main types are open-angle glaucoma and angle-closure glaucoma. Open-angle glaucoma accounts for 90% of all cases of glaucoma, progresses slowly, and is initially often asymptomatic, but leads to bilateral peripheral vision loss over time. With appropriate treatment to lower IOP (e.g., topical prostaglandins), progression can be stopped before severe damage occurs. Acute angle-closure glaucoma is characterized by the sudden onset of a painful, red, and hard eye in combination with frontal headache, blurry vision, and halos appearing around lights. Immediate initiation of medical therapy (e.g., timolol eye drops and IV acetazolamide) is crucial to rapidly decrease IOP and prevent vision loss. Chronic angle-closure glaucoma manifests and is managed similarly to open-angle glaucoma.

Epidemiology

  • Second leading cause of blindness in adults in the US following age-related macular degeneration (AMD)
  • ∼ 2.3 million cases of glaucoma in the US
    • Vision impairment in ∼ 10% of patients
    • Blindness in ∼ 5% of patients
    • Open-angle glaucoma is more common than angle-closure glaucoma.

References:[1][2]

Epidemiological data refers to the US, unless otherwise specified.

Overview

Important types of glaucoma
Open-angle glaucoma Angle-closure glaucoma
Risk factors
  • Age > 40 years
  • African descent
  • Diabetes mellitus
  • Myopia
  • Family history of glaucoma
  • Asian descent
  • Mydriasis (e.g., mydriatic drugs such as atropine)
Clinical features
  • Initially often asymptomatic
  • Bilateral, progressive visual field loss (from peripheral to central)
  • Sudden onset
    • Unilateral red, hard, and severely painful eye
    • Frontal headaches
    • Vomiting, nausea
    • Steamy cornea and blurred vision
    • Dilated, nonreactive pupil
Treatment
  • Prostaglandin eye drops or laser trabeculoplasty
  • In refractory cases: surgical trabeculectomy
  • Topical timolol, apraclonidine, and IV acetazolamide
  • Curative treatment: laser peripheral iridotomy
  • No mydriatic drugs
Overview of drugs used to treat glaucoma
Mechanism of IOP decrease Drugs Mechanism of action Adverse effects
↓ Synthesis of aqueous humor
  • Beta blocker
    • Timolol
    • Betaxolol
    • Carteolol
  • Blockage of sympathetic nerve fibers in the ciliary epithelium
  • No changes in vision or pupil
  • Hypotension
  • Alpha-1 agonist
    • Epinephrine
  • Via decrease in cAMP
  • Additional conjunctival vasoconstriction
  • Mydriasis
  • Blurry vision
  • Ocular hyperemia
  • Foreign body sensation
  • Ocular allergy (e.g., pruritus)
  • Contraindicated in angle-closure glaucoma
  • Alpha-2 agonists
    • Apraclonidine
    • Brimonidine
  • Via decrease in cAMP
  • Mydriasis
  • Blurry vision
  • Ocular hyperemia
  • Foreign body sensation
  • Ocular allergy (e.g., pruritus)
  • Carbonic anhydrase inhibitors
    • Acetazolamide (oral)
    • Methazolamide (oral)
    • Brinzolamide
    • Dorzolamide
  • Inhibits the action of carbonic anhydrase
  • No changes in vision or pupil
  • Non-anion gap metabolic acidosis
Aqueous humor outflow
  • PGF2α
    • Latanoprost
    • Travoprost
    • Bimatoprost
  • Decreases resistance through uveoscleral flow
  • Darkening of iris
  • Growth of eyelashes
  • Epithelial keratopathy
  • Direct parasympathomimetic (via M3)
    • Pilocarpine (specifically effective in acute angle closure glaucoma)
    • Carbachol
  • Indirect parasympathomimetic (M3)
    • Physostigmine
    • Echothiophate
  • Ciliary muscle contraction
  • Trabecular meshwork opening (into canal of Schlemm)
  • Miosis (via contraction of pupillary sphincter)
  • Cyclospasm (via contraction of ciliary muscle)

DIrty PARASites PROSper on ALPine BETonies: DIuretics, PARASympathomimetics, PROStaglandins, ALPha agonists, and BETa blockers are drugs for the treatment of glaucoma.

References:[2]

Pathophysiology

  • Aqueous humor is produced by the ciliary body on the iris, flows from the posterior chamber through the pupil into the anterior chamber, and then drains back into the venous system via the trabecular meshwork in the angle of the anterior chamber.
  • Physiologically, the flow of aqueous humor against resistance generates an average intraocular pressure (IOP) between 10–21 mm Hg.
  • Any process that disrupts the flow of aqueous humor (e.g., adhesion of the iris to the lens) may raise IOP and lead to optic nerve damage and visual impairment (e.g., glaucomatous optic neuropathy).
  • See “Pathophysiology” in “Open-angle glaucoma” and “Angle-closure glaucoma.”

References:[3][4]

Open-angle glaucoma

Definition

  • Open-angle glaucoma (also chronic glaucoma): generally bilateral, progressive loss of optic nerve fibers with open chamber angles (often with increased IOP), not caused by another systemic or local condition

Etiology [5]

  • Primary cause unclear
  • Risk factors [5]
    • Age > 40 years
    • Increased IOP
    • European or African descent
    • Diabetes mellitus
    • Familial predisposition
    • Myopia
    • Steroid use

Pathophysiology

  • Secondary clogging of the trabecular meshwork or reduced drainagegradual ↑ in IOP → vascular compression ischemia to the optic nerve → progressive visual impairment
  • Causes
    • Secondary clogging due to:
      • Inflammatory cells (e.g., uveitis)
      • Red blood cells (e.g., vitreous hemorrhage)
      • Material from retinal detachment in the aqueous humor
    • Reduced drainage due to:
      • Increased episcleral venous pressure
      • Damaged trabecular meshwork after a chemical injury

Clinical features [5]

  • Initially often asymptomatic
  • Over time, nonspecific symptoms such as mild headaches, impaired adaptation to darkness
  • Generally bilateral, progressive visual field loss (from peripheral to central)
  • Arcuate scotoma: arch-shaped scotoma that starts from the blind spot

Diagnostics [5]

  • Slit-lamp examination of the anterior segment: normal appearing anterior chamber angle
  • Tonometry
    • To measure IOP (standard values range between 10–21 mm Hg)
    • Elevated IOP may be seen in up to 40% of patients with primary open-angle glaucoma but is not a requirement for diagnosis. [5]
  • Gonioscopy: to rule out angle-closure glaucoma
  • Fundoscopy: cupping and pallor of optic disc, disc hemorrhage, diffuse or focal narrowing of the optic disc rim
  • Perimetry: visual field testing to detect blind spots in the visual field

Treatment of open-angle glaucoma [5]

  • Indicated in all patients diagnosed with open-angle glaucoma (even if asymptomatic)
  • Options include medical therapy, laser surgery, and open surgery.
  • Topical prostaglandins are most effective and usually used initially; other drugs (with a different mechanism) may be added if topical prostaglandins are unsuccessful.
    • No decrease in IOP with one drug: Discontinue and replace with another drug or treatment option.
    • Partial response to one drug: Consider combination therapy with other glaucoma medications or switch to an alternative single-agent therapy.
  • Goal of therapy (target IOP): ≥ 25% decrease in pretreatment IOP

Pharmacotherapy [5][6]

The following regimen is the most commonly followed and is also effective in patients with chronic angle-closure glaucoma refractory to laser peripheral iridotomy (see ''Treatment'' in “Angle-closure glaucoma” for further details).

  • Important considerations
    • Tailor regimen to the patient's comorbidities and tolerance.
    • Adherence to pharmacotherapy is crucial.
    • Advise patients to occlude their nasolacrimal ducts following the topical administration of drugs.
    • Patients should be continually assessed for disease progression and for local and systemic adverse effects.
  • Preferred first-line therapy: topical prostaglandin analogs ; [6]
    • Latanoprost
    • Travoprost
    • Bimatoprost
  • Alternative options
    • Topical beta blockers alone and/or alpha-2 agonists [6]
      • Beta blockers
        • Timolol
        • Betaxolol
      • Alpha-2 agonists
        • Brimonidine
        • Apraclonidine : generally used perioperatively in patients with refractory glaucoma [5]
    • Topical carbonic anhydrase inhibitors
      • Brinzolamide
      • Dorzolamide
  • Refractory glaucoma: oral carbonic anhydrase inhibitors
    • Acetazolamide
    • Methazolamide

Interventional therapy [5]

Procedures that lower IOP by facilitating drainage of aqueous humor

  • Laser trabeculoplasty
    • Indications
      • An alternative first-line treatment for patients with advanced disease at presentation
      • Glaucoma refractory to pharmacotherapy
      • Patients nonadherent or intolerant to pharmacotherapy
    • Procedure: use of a laser to thermally ablate the trabecular meshwork cells and improve aqueous outflow
    • Alternative: selective laser trabeculoplasty [7]
      • Pigmented cells of the trabecular meshwork are selectively targeted for thermal ablation.
      • Has a better safety profile than laser trabeculoplasty and may soon become the preferred first-line therapy for treatment-naive open-angle glaucoma [8][9]
  • Surgical trabeculectomy
    • Indications: the same as those for laser trabeculoplasty
    • Procedure: involves the creation of a tunnel (through excision of trabecular meshwork) from the anterior chamber to the subconjunctival space under a thin scleral flap
  • Tube shunt surgery
    • Indication: glaucoma refractory to trabeculectomy
    • Procedure: A small silicone tube is inserted into the anterior chamber of the eye through which aqueous humor is drained into a valved chamber that is placed on the sclera underneath the upper eyelid. [10]

Procedures that lower IOP by decreasing aqueous humor production

  • Cyclodestructive surgery
    • Indication: glaucoma refractory to other treatment options
    • Procedure: laser or cryosurgical destruction of the ciliary body

Prevention [5]

  • General screening for glaucoma is not considered cost-effective but is currently recommended in the following patient groups:
    • Personal history of diabetes mellitus
    • Family history of glaucoma
    • African Americans > 50 years of age
    • Hispanic Americans > 65 years of age

Angle-closure glaucoma

Definition [6][11][12][13]

  • Angle-closure glaucoma (also closed-angle glaucoma): sudden and sharp increase in IOP caused by an obstruction of aqueous outflow (most commonly as a result of an occlusion of the iridocorneal angle; ) and associated with optic neuropathy and visual field defects [11][14]
  • Acute angle-closure glaucoma (AACG): sudden obstruction of the iridocorneal angle causing a rapid, acutely symptomatic, and vision-threatening elevation of IOP, often > 30 mm Hg [11][15]
  • Chronic angle-closure glaucoma: chronic obstruction of the iridocorneal angle with peripheral anterior synechiae resulting in an insidious and progressive rise in IOP that typically remains asymptomatic until glaucomatous optic neuropathy and irreversible visual field defects have developed [6]
  • Angle-closure suspect: normal IOP with iridotrabecular contact on gonioscopy [11]

Etiology/risk factors

  • Anatomic features predisposing to angle closure: shallow anterior chamber (e.g., hyperopia, short eye)
  • Older age
  • Female sex
  • Asian or Inuit ethnicity [6][16]
  • Eye injury with scarring and adhesions
  • Rubeosis iridis
  • Mydriasis
    • Drug-induced: anticholinergics (e.g., atropine) , sympathomimetics, decongestants
    • Darkness
    • Stress/fear response

Pathophysiology [11][12][13][17][18]

  • Common pathophysiology of angle-closure glaucoma: blockage of the trabecular meshwork → ↓ drainage of aqueous humor from the eye IOP
  • Primary angle-closure glaucoma: glaucoma due to an anatomical variant of ocular structure(s) that narrows the iridocorneal angle and increases the likelihood of trabecular meshwork obstruction
    • Shallow chamber depth (enhanced by mydriasis)
    • Small anterior segment of the eye
    • Plateau iris configuration
      • Most common cause of angle-closure glaucoma in individuals < 50 years of age [19]
      • An anatomical variant in which the iris is abnormally inserted in a more anterior position onto the ciliary body and lies on a horizontal plane (compared to its normal slightly convex plane), thus crowding the trabecular meshwork
      • The anterior chamber depth remains normal.
  • Secondary angle-closure glaucoma: glaucoma due to acquired conditions that occlude the iridocorneal angle with/without a pupillary block
    • Pupillary block ; ↑ pressures in the posterior chamber of the eye → iris bulging forward → peripheral iris pressing against the cornea → narrowing of iridocorneal angle (anterior chamber angle) → blockage of the trabecular meshwork
      • Examples of conditions causing pupillary block
        • Inflammatory conditions (e.g., uveitis) causing posterior synechiae between the iris and lens
        • Anterior dislocation of the lens (ectopia lentis)
        • Enlargement of the lens (e.g., mature cataract)
    • Direct blockage of the trabecular meshwork (i.e., without a pupillary block); examples include:
      • Inflammatory conditions causing peripheral anterior synechiae between the iris and cornea
      • Rubeosis iridis: hypoxia and the release of vasoproliferative substances (common in retinal ischemia due to central retinal vein occlusion or in diabetes mellitus) → angiogenesis of the iris and the ciliary body → narrowing of the anterior chamber angle → neovascular glaucoma

Clinical features

  • Acute angle-closure glaucoma
    • Sudden onset of symptoms
    • Unilaterally inflamed, reddened, and severely painful eye (hard on palpation)
    • Frontal headaches, vomiting, nausea
    • Blurred vision and halos seen around light
    • Cloudy cornea (opacification)
    • Mid-dilated, irregular, unresponsive pupil
    • Complications: rapid permanent vision loss due to ischemia and atrophy of the optic nerve
  • Chronic angle-closure glaucoma
    • Asymptomatic in early stages
    • Progressive vision loss beginning with peripheral fields of vision (due to gradually increasing optic nerve compression)

Acute angle-closure glaucoma is a medical emergency, as it can cause permanent vision loss if left untreated.

Diagnostics

Approach [6][11][12][13]

Acute angle-closure glaucoma is vision-threatening and requires emergency ophthalmology evaluation as soon as the clinical diagnosis is suspected.

  • Both eyes should be evaluated even if symptoms are unilateral. [11]
  • A clinical diagnosis of angle-closure glaucoma is confirmed with the following findings:
    • Elevated IOP (> 21 mm Hg) on tonometry [6][13][14]
    • Narrowing/closure of the iridocorneal angle (i.e., iridotrabecular contact) on gonioscopy or slit-lamp examination
  • Tests to assess for glaucomatous damage should be performed in all patients.
    • Optic disc changes (slit-lamp examination or undilated fundoscopy)
    • Visual acuity
    • Visual field testing
  • Provocative testing (e.g., placing the patient in a dark room, administering mydriatics) is not recommended in acute angle-closure glaucoma because it is time-consuming, exacerbates symptoms, and is of questionable clinical significance. [6][11][13]
  • Other causes of painful red eye (especially uveitis) and/or headache with ocular pain (e.g., migraine) should be considered if diagnostic findings are inconclusive.

Do not use mydriatic drugs (e.g., atropine and epinephrine) during ophthalmologic examination in patients with acute angle-closure glaucoma! Moreover, do not cover the eye, as darkness induces mydriasis and worsens the condition. [11]

Tonometry [20][21]

  • Indication: all patients with suspected glaucoma
  • Procedure: measurement of IOP by placing a probe over the cornea
  • Characteristic findings [11][13]
    • Acute angle-closure glaucoma: IOP is typically > 30 mm Hg. [6][11][15]
    • Chronic angle-closure glaucoma: IOP > 21 mm Hg
    • Angle-closure suspect: normal IOP [6][11][13]

Gonioscopy [12]

  • Indications [6][11][13]
    • Gold-standard test to assess the iridocorneal angle in suspected angle-closure glaucoma
    • To distinguish between primary and secondary causes of angle closure (see ''Pathophysiology'')
  • Characteristic findings [6][11][13]
    • Narrowing or closure of the iridocorneal angle (i.e., ≥ 180º iridotrabecular contact)
    • Etiology of narrowed/closed iridocorneal angle may be apparent, such as: [13]
      • Peripheral anterior synechiae
      • Plateau iris configuration

Slit-lamp examination [6][11][18]

  • Indication: to evaluate the anterior chamber and optic disc in all patients with suspected glaucoma
  • Supportive findings [6]
    • Acute and chronic angle-closure glaucoma: shallow anterior chamber
    • Acute angle-closure glaucoma
      • Cornea: cloudy or hazy
      • Pupil: mid-dilated (4–6 mm); sluggish pupillary reaction
    • Chronic angle-closure glaucoma: signs of glaucomatous optic neuropathy [11][18][22]
      • Increased cup-to-disc ratio > 0.5
      • Asymmetrical cup-to-disc ratio between eyes
      • Superficial hemorrhages within the optic disc
      • Focal thinning and pallor of the neuroretinal rim

Direct fundoscopy (with undilated pupils) [6][11][18]

  • Indication: an alternative to slit-lamp examination to assess for optic disc damage
  • Supportive findings
    • Acute angle-closure glaucoma: edema and microhemorrhages of the optic disc with or without signs of glaucomatous optic neuropathy [18]
    • Chronic angle-closure glaucoma: signs of glaucomatous optic neuropathy [18]

Do not dilate the pupils to evaluate the fundus in suspected glaucoma.

Visual acuity [11][23]

  • Indication: all patients with glaucoma
  • Supportive findings
    • Acute angle-closure glaucoma: Corneal edema may decrease visual acuity even in the absence of glaucomatous optic neuropathy. [11]
    • Chronic angle-closure glaucoma: There may be decreased central vision or complete blindness in advanced disease. [23]

Visual field testing [6][13][24]

  • Indication: all patients with glaucoma
  • Techniques
    • Confrontation visual field exam: preferred in the ER when an ophthalmologist is not immediately available
    • Automatic static perimetry: preferred if an ophthalmologist is available
  • Characteristic findings
    • Glaucomatous visual field defects: a characteristic pattern of visual field defects as a result of glaucomatous optic neuropathy [18][24]
      • Early-stage: arcuate or double arcuate (ring) scotoma
        • Loss of peripheral vision especially of the superior and/or inferior hemifields
        • Sparing of central vision
      • Advanced stage
        • Tunnel vision: further constriction of peripheral vision
        • Total or near-total blindness: loss of peripheral and central vision with or without sparing of the temporal field

Treatment of acute angle-closure glaucoma [6][11][13][15][25]

Acute angle-closure glaucoma is an emergency and should be initially managed with IOP-decreasing medications that have a rapid onset of action. Once IOP has decreased, patients should undergo a definitive procedure as soon as possible to prevent recurrence.

General considerations

  • Emergency ophthalmology consultation
  • Place the patient in a supine position.
  • Ensure the contralateral eye has been evaluated for urgent treatment, even if it is asymptomatic. [11]
  • Administer supportive care as needed.
    • Analgesics (see “Pain management”)
    • Antiemetics (e.g., ondansetron )

Initial pharmacotherapy

  • Indication: initiate in all patients as soon as a diagnosis of acute angle-closure glaucoma is made [6][11][13][15]
  • Initial pharmacological regimen: There is currently no standardized recommendation for empiric management of acute angle-closure glaucoma. The following regimen may be followed with due consideration of any comorbidities. [6][11][13][15]
    • Topical ophthalmic therapy. Administer the following eye drops in succession, one minute apart: [15]
      • Direct parasympathomimetic: pilocarpine [6][13][15]
      • Alpha-2 agonist: apraclonidine [15]
      • Beta blocker: timolol [15]
    • PLUS a systemic carbonic anhydrase inhibitor ; [26]
      • Acetazolamide [6][15]
      • OR methazolamide [6][11][15]
    • Consider also the following alternatives:
      • Betaxolol [6]
      • Brinzolamide [6]
      • Dorzolamide [6]
      • Levobunolol [6]
      • Brimonidine [6]
  • If IOP is still elevated after 30–60 minutes: The following should be given only under the guidance of an ophthalmologist. [15][25]
    • Repeat eye drops from above up to three times. [15]
    • Consider a systemic hyperosmotic agent if IOP remains high after 60 minutes of initiating therapy. [13][25]
      • In patients with nausea: IV mannitol
      • In patients without significant nausea: [25]
        • Patients without diabetes: oral glycerine [25]
        • Patients with diabetes: oral isosorbide [11]
  • If IOP is decreasing: Examine for other signs of resolution of the acute attack. [6][13]
    • Symptomatic improvement (decreased pain and nausea; improvement of vision)
    • Clear cornea (resolution of corneal edema)
    • Decreased conjunctival hyperemia
    • Normal pupillary size and reaction

Urgent interventional therapy

  • Anterior chamber paracentesis
    • Indication: Consider for vision-threatening elevation in IOP refractory to medical management. [11][27]
    • Procedure: controlled drainage of some of the aqueous humor through an opening created at the limbus [28][29]
    • Important consideration: Anterior chamber paracentesis is a temporizing measure; patients will still require definitive treatment with laser peripheral iridotomy. [27]
  • Urgent laser peripheral iridotomy (see ''Interventional therapy'' for details)
    • Indication: all patients within 24–48 hours of resolution of the acute attack [6]

Topical pilocarpine becomes effective only once IOP decreases to < 40 mm Hg.

Treatment of chronic primary angle-closure glaucoma [6][11][12]

Chronic angle-closure glaucoma with pupillary block should be initially managed with laser surgery (e.g., peripheral iridotomy) or open surgery (iridectomy) to prevent the progression of glaucomatous optic neuropathy and consequent visual field loss. Long-term pharmacotherapy is required if IOP elevation is refractory to the intervention or in patients without pupillary block.

  • Laser peripheral iridotomy (LPI): preferred first-line therapy if pupillary block is suspected (see “Interventional therapy” for details) [6][30]
  • Maintenance pharmacotherapy: similar to that of open-angle glaucoma (see “Treatment of open-angle glaucoma” for further details) [6]
    • Indications
      • Persistently elevated IOP despite iridotomy
      • Chronic primary angle-closure glaucoma without pupillary block

Interventional therapy [6][11][12][13]

Acute angle-closure glaucoma and chronic primary angle-closure with pupillary block

  • Laser peripheral iridotomy (LPI)
    • Indications [6]
      • Standard of care for acute angle-closure glaucoma as soon as the acute attack is resolved and the cornea becomes clear [6][12]
      • First-line therapy for chronic primary angle-closure glaucoma with pupillary block
      • Prophylactic therapy for the contralateral eye in patients with unilateral angle-closure glaucoma [12][14]
    • Procedure: the creation of a hole in the peripheral iris to allow aqueous humor to bypass the pupillary block using a laser (preferably neodymium:YAG) [6]
    • Disadvantages [31][32]
      • Risk of closure of the iridotomy
      • Post-operative IOP
      • Laser burn
      • Transient blurred vision
      • Progression to cataract formation
  • Laser peripheral iridoplasty (gonioplasty)
    • Indication: persistently elevated IOP despite a patent LPI [6]
    • Procedure: creation of burn contractures in the peripheral iris with an argon laser to pull the peripheral iris away from the iridocorneal angle
  • Surgical peripheral iridectomy [11][14][30]
    • Indication: an alternative to LPI in patients with acute/chronic angle-closure glaucoma with pupillary block [11][30]
    • Procedure: the surgical excision of a small amount of iris tissue to allow for aqueous flow
    • Disadvantages
      • Costly
      • Postoperative recovery period
      • Surgical complications

Chronic primary angle-closure glaucoma without pupillary block [6]

  • Interventions are similar to those for open-angle glaucoma. Examples include:
    • Surgical trabeculectomy
    • Tube shunt (aqueous shunt) implantation [10]

Secondary angle-closure glaucoma [6][30]

  • Surgery for the underlying cause, such as:
    • Cataract surgery
    • Goniosynechialysis

Congenital glaucoma

Epidemiology

  • < 1% of children are born with the condition in the US.
  • Bilateral in ∼ 75% of cases
  • Most cases are diagnosed within the first year of life.

Etiology

  • Primary congenital glaucoma: sporadic occurrence or autosomal recessive inheritance
  • Secondary congenital glaucoma: due to trauma, infection, tumor, other congenital ocular abnormalities (e.g., aniridia), or glaucoma associated with systemic congenital abnormalities (e.g., phakomatoses, Down syndrome)

Pathophysiology

  • Primary: isolated improper development of the trabecular meshwork → ↓ drainage of aqueous humor → IOP
  • Secondary: malformation of the trabecular meshwork and iris or cornea → ↓ drainage of aqueous humor → IOP

Clinical features

  • Buphthalmos: a condition of an enlarged eyeball which most commonly is associated with congenital glaucoma caused by elevated intraocular pressure
  • Enlarged corneal diameter
  • Corneal clouding
  • Photophobia
  • Excessive tearing (epiphora)
  • In secondary congenital glaucoma, symptoms of the underlying disease

Diagnostics

  • ↑ Corneal diameter and ↑ diameter are diagnostic.
    • Gonioscopy
    • Tonometry
    • Corneal measurement
    • Ophthalmoscopy: optic nerve cupping and pallor
  • Genetic testing: e.g., CYP1B1 gene
  • In secondary congenital glaucoma, further diagnostics depending on the underlying disease

Therapy

  • Surgery

External Resources

References

  1. "Understand Your Glaucoma Diagnosis". http://www.glaucoma.org/treatment/understand-your-glaucoma-diagnosis.php. [2012-09-06]
  2. Ashar B, Miller R, Sisson S. "Johns Hopkins Internal Medicine Board Review 2010-2011". Elsevier Health Sciences. (2010). ISBN: 9780323080453
  3. Johnstone MA. "Intraocular pressure regulation: Findings of pulse-dependent trabecular meshwork motion lead to unifying concepts of intraocular pressure homeostasis". J Ocul Pharmacol Ther. 30(2-3). :88-93. (2014)
  4. "Intraocular Pressure". https://www.aao.org/bcscsnippetdetail.aspx?id=f010bbf6-3f3e-486b-b5cd-0ad86ddb9d74. [2017-01-01]
  5. "Primary Open-Angle Glaucoma preferred practice pattern". https://www.aao.org/preferred-practice-pattern/primary-open-angle-glaucoma-ppp-2015. [2015-11-01]
  6. "Angle-Closure Glaucoma". https://web.archive.org/web/20230602085020/https://www.aao.org/education/munnerlyn-laser-surgery-center/angleclosure-glaucoma-19. [2013-12-18]
  7. Jha B, Bhartiya S, Sharma R, Arora T, Dada T. "Selective Laser Trabeculoplasty: An Overview.". Journal of current glaucoma practice. 6(2). :79-90. (2012)
  8. Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. "Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial". The Lancet. 393(10180). :1505-1516. (2019)
  9. Ang M, Tham CC, Sng CCA. "Selective laser trabeculoplasty as the primary treatment for open angle glaucoma: time for change?". Eye. 34(5). :789-791. (2019)
  10. Wang J, Barton K. "Aqueous shunt implantation in glaucoma.". Taiwan journal of ophthalmology. 7(3). :130-137. (2017)
  11. Prum BE, Herndon LW, Moroi SE, et al. "Primary Angle Closure Preferred Practice Pattern® Guidelines". Ophthalmology. 123(1). :P1-P40. (2016)
  12. Razeghinejad MR, Myers JS. "Contemporary approach to the diagnosis and management of primary angle-closure disease". Surv Ophthalmol. 63(6). :754-768. (2018)
  13. "Care of the Patient with Primary Angle Closure Glaucoma". https://web.archive.org/web/20200716054025/https://www.aoa.org/documents/optometrists/CPG-5.pdf. [2001-01-01]
  14. Perera S, Amerasinghe N, Aung T. "Angle closure glaucoma". Elsevier. :193-199. (2010). ISBN: 9780702029837
  15. Pokhrel PK, Loftus SA. "Ocular Emergencies". American Family Physician. 76. :829–836. (2007)
  16. Tham Y-C, Li X, Wong TY, et al. "Global prevalence of glaucoma and projections of glaucoma burden through 2040". Ophthalmology. 121(11). :2081-2090. (2014)
  17. Edmunds B, Loh RA, Fenerty C, Papadopoulos M. "Secondary Glaucoma: Glaucoma Associated with Acquired Conditions". American Academy of Ophthalmology. (2015)
  18. Sihota, Tandon R. "Parsons' Diseases of the Eye". Elsevier India. (2019). ISBN: 9788131254165
  19. Stamper RL, Lieberman MF, V. Drake M. "Becker-Shaffer's Diagnosis and Therapy of the Glaucomas". Elsevier Health Sciences. (2009). ISBN: 9780323023948
  20. Perkins ES. "Hand-held applanation tonometer.". Br J Ophthalmol. 49(11). :591-593. (1965)
  21. Arora R, Bellamy H, Austin M. "Applanation tonometry: a comparison of the Perkins handheld and Goldmann slit lamp-mounted methods.". Clinical ophthalmology (Auckland, N.Z.). 8. :605-10. (2014)
  22. Distelhorst JS, Hughes GM. "Open-angle glaucoma.". Am Fam Physician. 67(9). :1937-44. (2003)
  23. Gupta D, Chen PP. "Glaucoma.". Am Fam Physician. 93(8). :668-74. (2016)
  24. Gazzard G. "The Severity and Spatial Distribution of Visual Field Defects in Primary Glaucoma". Arch Ophthal. 120(12). :1636. (2002)
  25. Murray D. "Emergency management: angle-closure glaucoma.". Community eye health. 31(103). :64. (2018)
  26. Giaconi JA, Law SK, Nouri-Mahdavi K, Coleman AL, Caprioli J. "Pearls of Glaucoma Management". Springer. (2016). ISBN: 9783662490426
  27. Lam DS., Chua JK., Tham CC., Lai JS. "Efficacy and safety of immediate anterior chamber paracentesis in the treatment of acute primary angle-closure glaucoma". Ophthalmology. 109(1). :64-70. (2002)
  28. Reichman E. "Emergency Medicine Procedures". McGraw-Hill. (2013). ISBN: 9780071613521
  29. Cioboata M, Anghelie A, Chiotan C, et al. "Benefits of anterior chamber paracentesis in the management of glaucomatous emergencies.". Journal of medicine and life. 7 Spec No. 2. :5-6. (2014)
  30. See JL, Aquino MC, Aduan J, Chew PT. "Management of angle closure glaucoma.". Indian J Ophthalmol. 59 Suppl. :S82-7. (2011)
  31. Spaeth GL, Idowu O, Seligsohn A, et al. "The Effects of Iridotomy Size and Position on Symptoms Following Laser Peripheral Iridotomy". J Glaucoma. 14(5). :364-367. (2005)
  32. Vijaya L, Asokan R, Panday M, George R. "Is prophylactic laser peripheral iridotomy for primary angle closure suspects a risk factor for cataract progression? The Chennai Eye Disease Incidence Study.". Br J Ophthalmol. 101(5). :665-670. (2017)
  33. Dabasia PL, Edgar DF, Lawrenson JG. "Methods of measurement of the anterior chamber angle Part 2: Screening for angle closure and angle closure glaucoma". Optometry in Practice. 14(4). :147-154. (2013)
  34. Jacobs DS. "Open-angle glaucoma: Treatment". UpToDate. UpToDate. https://www.uptodate.com/contents/open-angle-glaucoma-treatment?source=search_result&search=glaucoma%20screening&selectedTitle=2~18#H6891053. [2016-09-30]
  35. "SLT or Drops? Take Your Pick"
  36. Weizer JS. "Angle-closure glaucoma". UpToDate. UpToDate. https://www.uptodate.com/contents/angle-closure-glaucoma?source=search_result&search=glaucoma%20treatment&selectedTitle=2~150#H11. [2015-12-22]
  37. Freedman J. "Acute Angle-Closure Glaucoma". WebMD. http://emedicine.medscape.com/article/798811-overview. [2016-08-22]
  38. Trattler W, Kaiser P, Friedman N. "Review of Ophthalmology". Elsevier Saunders. (2012). ISBN: 9781437727036
  39. "Are You at Risk For Glaucoma?". http://www.glaucoma.org/glaucoma/are-you-at-risk-for-glaucoma.php. [2011-01-13]
  40. Biggerstaff KS. "Primary Open-Angle Glaucoma". WebMD. http://emedicine.medscape.com/article/1206147-overview. [2016-09-15]
  41. Jacobs DS. "Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis". UpToDate. UpToDate. https://www.uptodate.com/contents/open-angle-glaucoma-epidemiology-clinical-presentation-and-diagnosis. [2016-01-22]
  42. Rhee DJ. "Drug-Induced Glaucoma". WebMD. http://emedicine.medscape.com/article/1205298-overview. [2014-07-29]
  43. Zhou M, Wang W, Huang W, Zhang X. "Diabetes mellitus as a risk factor for open-angle glaucoma: A systematic review and meta-analysis". PLoS ONE. 9(8). :e102972. (2014)
  44. Bigger JF. "Glaucoma with elevated episcleral venous pressure". South Med J. 68(11). :1444-1448. (1975)
  45. "Angle-Closure Glaucoma". https://www.merckmanuals.com/professional/eye-disorders/glaucoma/angle-closure-glaucoma. [2019-10-01]
  46. "Acute Closed Angle Glaucoma". https://www.ncbi.nlm.nih.gov/books/NBK430857/. [2019-01-01]
  47. Gorbaty JD, Hsu JE, Gee AO. "Classifications in Brief: Rockwood Classification of Acromioclavicular Joint Separations". Clinical Orthopaedics and Related Research®. 475(1). :283-287. (2016)
  48. Lee TL, Yuxin Ng J, Nongpiur ME, et al. "Intraocular pressure spikes after a sequential laser peripheral iridotomy for angle closure.". J Glaucoma. 23(9). :644-8. (2014)
  49. Mantravadi AV, Vadhar N. "Glaucoma". Primary Care: Clinics in Office Practice. 42(3). :437-449. (2015)
  50. "Laser Trabeculoplasty: Questions in Clinical Practice". https://www.aao.org/munnerlyn-laser-surgery-center/laser-trabeculoplasty-questions-in-clinical-practi. [2013-10-31]
  51. Lusthaus J, Goldberg I. "Current management of glaucoma". Med J Aust. 210(4). :180-187. (2019)
  52. Gupta S, Galpalli N, Agrawal S, Srivastava S, Saxena R. "Recent advances in pharmacotherapy of glaucoma". Indian J Pharmacol. 40(5). :197. (2008)